Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Stéphane Pyronnet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9562-5112; OpenAlex author ID A5058448191. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs. Co-author DOI 10.1002/advs.202515740↗
  2. Translational alterations in pancreatic cancer: a central role for the integrated stress response. Co-author DOI 10.1093/narcan/zcac031↗
  3. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
  4. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer Co-author DOI 10.1016/j.pan.2021.05.117↗
  5. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. Co-author DOI 10.15252/emmm.202012010↗
  6. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. Co-author DOI 10.1172/jci.insight.121951↗
  7. Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2016.10.010↗
  8. Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL. Last author DOI 10.1038/s41419-017-0001-z↗
  9. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts. Co-author DOI 10.18632/oncotarget.9296↗
  10. Increase in PI3K signalling mimics mutated-Kras induction of pancreatic cancer First author DOI 10.1016/j.clinre.2013.04.006↗
  11. EZH2 links pancreatitis to tissue regeneration and pancreatic cancer. First author DOI 10.1016/j.clinre.2012.05.010↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Corinne Bousquet · 8 shared papers, 2016–2026 · strength 0.90
  2. Yvan Martineau · 7 shared papers, 2016–2026 · strength 0.81
  3. Christine Jean · 7 shared papers, 2016–2026 · strength 0.71
  4. Sauyeun Shin · 4 shared papers, 2019–2026 · strength 0.58
  5. Cindy Neuzillet · 4 shared papers, 2020–2026 · strength 0.49
  6. Rémi Samain · 5 shared papers, 2016–2021 · strength 0.41
  7. Rémy Nicolle · 3 shared papers, 2021–2026 · strength 0.41
  8. Juan Iovanna · 2 shared papers, 2021–2026 · strength 0.32
  9. Nelson Dusetti · 2 shared papers, 2021–2026 · strength 0.32
  10. Emilie Decaup · 3 shared papers, 2016–2020 · strength 0.22
  11. Nicolas Alejandro Fraunhoffer · 1 shared paper, 2026 · strength 0.21
  12. Jérôme Raffenne · 2 shared papers, 2021 · strength 0.20
  13. Jerome F. Cros · 2 shared papers, 2020–2021 · strength 0.18
  14. Richard Tomasini · 2 shared papers, 2020–2021 · strength 0.18
  15. Romain Baer · 2 shared papers, 2013–2019 · strength 0.14
  16. Julie Guillermet‐Guibert · 2 shared papers, 2013–2019 · strength 0.14
  17. Matteo Ponzo · 1 shared paper, 2021 · strength 0.09
  18. Jérémy Nigri · 1 shared paper, 2021 · strength 0.09
  19. Ilaria Cascone · 1 shared paper, 2021 · strength 0.09
  20. Sonia Zaghdoudi · 1 shared paper, 2020 · strength 0.08
  21. Oliver M.T. Pearce · 1 shared paper, 2020 · strength 0.08
  22. David Müller · 1 shared paper, 2019 · strength 0.08
  23. Satvinder Mudan · 1 shared paper, 2017 · strength 0.07
  24. Androulla Elia · 1 shared paper, 2017 · strength 0.07
  25. Charline Lasfargues · 1 shared paper, 2012 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.